Frederic Brosseron

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8683103/publications.pdf

Version: 2024-02-01

23 papers 5,515 citations

623734 14 h-index 752698 20 g-index

28 all docs 28 docs citations

times ranked

28

10208 citing authors

#	Article	IF	CITATIONS
1	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. Neuron, 2022, 110, 1009-1022.e4.	8.1	27
2	Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease. Neurology, 2022, 99, .	1.1	24
3	Interrelations of AlzheimerÂ's disease candidate biomarkers neurogranin, fatty acidâ€binding protein 3 and ferritin to neurodegeneration and neuroinflammation. Journal of Neurochemistry, 2021, 157, 2210-2224.	3.9	15
4	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
5	Major Surgery Affects Memory in Individuals with Cerebral Amyloid-Î ² Pathology. Journal of Alzheimer's Disease, 2021, 79, 863-874.	2.6	9
6	Longitudinal Neurocognitive and Pulmonological Profile of Long COVID-19: Protocol for the COVIMMUNE-Clin Study. JMIR Research Protocols, 2021, 10, e30259.	1.0	8
7	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. Neurology, 2021, 96, .	1.1	72
8	Multiâ€cohort profiling reveals elevated CSF levels of brainâ€enriched proteins in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2021, 8, 1456-1470.	3.7	19
9	SFRP1 modulates astrocyteâ€toâ€microglia crosstalk in acute and chronic neuroinflammation. EMBO Reports, 2021, 22, e51696.	4.5	27
10	A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659.	6.9	29
11	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimer's and Dementia, 2020, 16, 292-304.	0.8	29
12	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum. NeuroImage: Clinical, 2020, 28, 102495.	2.7	17
13	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSFâ€ADâ€pathology: Data from the DELCODE Study. Alzheimer's and Dementia, 2020, 16, e044741.	0.8	1
14	Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143.	1.1	58
15	NLRP3 inflammasome activation drives tau pathology. Nature, 2019, 575, 669-673.	27.8	782
16	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	6.2	131
17	Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 25.	6.2	74
18	P1â€379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P443.	0.8	0

#	Article	IF	CITATIONS
19	P3â€327: NEUROPSYCHIATRIC SYMPTOMS IN ATâ€RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AE BIOMARKERS: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1206.	0.8	0
20	P3â€366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES C ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1228.	0.8	0
21	P4â€068: LEVELS OF THE ASTROCYTEâ€DERIVED PROTEINS GFAP AND S100B IN THE CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND ALZHEIMER'S DISEASE PATIENTS AT DIFFERENT DISEASE STAGES. Alzheimer's and Dementia, 2018, 14, P1458.	0.8	1
22	[P2–088]: CHRONIC AND ACUTE SYSTEMIC INFLAMMATION AND LONGâ€∓ERM COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P640.	0.8	2
23	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405.	10.2	4,129